Choong ANG Vaccine Laboratory

072020 · KOSDAQ · Health Care · SMALL CAP

Provisional Q1 2026 results.

Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q1 2026: revenue of US$8.72M (−4.9% year on year), operating profit of US$2.07M (+31% year on year) and net income of US$2.31M (+57.6% year on year).

Earnings(Operating results (preliminary) (fair disclosure))· FILED 2026-05-06· RCEPT 20260506900261

US$8.72MRevenue
−4.9%Revenue vs a year earlier
US$2.07MOperating profit

Converted at 1 USD ≈ ₩1,444.45 (filing-date rate, 2026-05-06 close)

What happened

Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q1 2026: revenue of US$8.72M (−4.9% year on year), operating profit of US$2.07M (+31% year on year) and net income of US$2.31M (+57.6% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$8.72M
Revenue vs a year earlier−4.9%
Operating profitUS$2.07M
Net incomeUS$2.31M
PeriodQ1 2026 (separate)
Filed2026-05-06, Operating results (preliminary) (fair disclosure)
SourceDART rcept 20260506900261 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-05-06 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.